Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials

Allison N. DuRoss, Jack Phan, Alexander J. Lazar, Joshua M. Walker, Alexander R. Guimaraes, Carole Baas, Sunil Krishnan, Charles R. Thomas, Conroy Sun, Alexander F. Bagley

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Original languageEnglish (US)
Article numbere1867
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Issue number3
StatePublished - May 1 2023


  • dose enhancement
  • metal nanoparticles
  • nanoparticle
  • radiosensitizer

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering


Dive into the research topics of 'Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials'. Together they form a unique fingerprint.

Cite this